Zura Bio Limited Class A Ordinary Shares ZURA
i
Market datapartial · fetched 2026-11-06T21:24:51.266Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-06T21:20:49.444142694Z
FundamentalsAlpha Vantage · unavailable
Zura Bio Limited Class A Ordinary Shares options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 2.93 | 403.9% | 44.1% | |||
| 25Δ | 9.99 | 416.1% | 150.3% | 3.35 | 409.7% | 39.6% |
| 30Δ | 9.36 | 437.6% | 137.9% | 3.78 | 415.5% | 35.1% |
| 35Δ | 8.68 | 454.1% | 123.9% | 4.26 | 423.3% | 31.2% |
| 40Δ | 7.89 | 463.9% | 107.8% | 4.80 | 433.2% | 28.0% |
| 45Δ | 7.06 | 464.9% | 90.6% | 5.38 | 437.0% | 24.7% |
| 50Δ | 6.20 | 457.4% | 72.5% | 5.97 | 437.1% | 21.5% |
| 55Δ | 5.12 | 400.7% | 47.5% | 6.43 | 420.0% | 18.4% |
| 60Δ | 4.52 | 367.2% | 34.8% | 6.88 | 401.9% | 15.3% |
| 65Δ | 3.99 | 338.6% | 24.0% | 7.33 | 383.7% | 12.2% |
| 70Δ | 3.66 | 332.1% | 19.8% | 8.39 | 393.0% | 9.9% |
| 75Δ | 3.32 | 325.6% | 15.6% | |||
| 80Δ | 2.98 | 319.1% | 11.4% | |||
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 2.93
- IV
- 403.9%
- B/E move
- 44.1%
25Δ
- Pseudo strike
- 9.99
- IV
- 416.1%
- B/E move
- 150.3%
- Pseudo strike
- 3.35
- IV
- 409.7%
- B/E move
- 39.6%
30Δ
- Pseudo strike
- 9.36
- IV
- 437.6%
- B/E move
- 137.9%
- Pseudo strike
- 3.78
- IV
- 415.5%
- B/E move
- 35.1%
35Δ
- Pseudo strike
- 8.68
- IV
- 454.1%
- B/E move
- 123.9%
- Pseudo strike
- 4.26
- IV
- 423.3%
- B/E move
- 31.2%
40Δ
- Pseudo strike
- 7.89
- IV
- 463.9%
- B/E move
- 107.8%
- Pseudo strike
- 4.80
- IV
- 433.2%
- B/E move
- 28.0%
45Δ
- Pseudo strike
- 7.06
- IV
- 464.9%
- B/E move
- 90.6%
- Pseudo strike
- 5.38
- IV
- 437.0%
- B/E move
- 24.7%
50Δ
- Pseudo strike
- 6.20
- IV
- 457.4%
- B/E move
- 72.5%
- Pseudo strike
- 5.97
- IV
- 437.1%
- B/E move
- 21.5%
55Δ
- Pseudo strike
- 5.12
- IV
- 400.7%
- B/E move
- 47.5%
- Pseudo strike
- 6.43
- IV
- 420.0%
- B/E move
- 18.4%
60Δ
- Pseudo strike
- 4.52
- IV
- 367.2%
- B/E move
- 34.8%
- Pseudo strike
- 6.88
- IV
- 401.9%
- B/E move
- 15.3%
65Δ
- Pseudo strike
- 3.99
- IV
- 338.6%
- B/E move
- 24.0%
- Pseudo strike
- 7.33
- IV
- 383.7%
- B/E move
- 12.2%
70Δ
- Pseudo strike
- 3.66
- IV
- 332.1%
- B/E move
- 19.8%
- Pseudo strike
- 8.39
- IV
- 393.0%
- B/E move
- 9.9%
75Δ
- Pseudo strike
- 3.32
- IV
- 325.6%
- B/E move
- 15.6%
- Pseudo strike
- IV
- B/E move
80Δ
- Pseudo strike
- 2.98
- IV
- 319.1%
- B/E move
- 11.4%
- Pseudo strike
- IV
- B/E move
Options history
Table
| Date | IV (%) |
|---|---|
| 236.13% | |
| 257.90% |
Biotechnology
ZVRA
Zevra Therapeutics, Inc., a rare disease company melding science, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The…
More →ZYME
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops and markets biotherapeutic products for the treatment of cancer. The company is headquartered in…
More →AARD
Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the…
More →ABCL
AbCellera Biologics Inc. develops an antibody discovery platform. The company is headquartered in Vancouver, Canada.
More →ABEO
Description unavailable
More →ABOS
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, is dedicated to developing therapies for the treatment of Alzheimer's disease and other neurodegenerative…
More →